These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 30085048)

  • 41. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.
    Mallick I; Das A; Arunsingh M
    Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):260-264. PubMed ID: 30718087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
    Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A
    Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer.
    Kozuka T; Nakano M; Hashimoto M; Gomi K; Murofushi KN; Sumi M; Yonese J; Oguchi M
    Jpn J Radiol; 2017 May; 35(5):269-278. PubMed ID: 28281047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels.
    Wortel RC; Heemsbergen WD; Smeenk RJ; Witte MG; Krol SDG; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1243-1252. PubMed ID: 28943074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
    Nakamura K; Mizowaki T; Inokuchi H; Ikeda I; Inoue T; Kamba T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2018 Feb; 23(1):158-164. PubMed ID: 28756594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer.
    McDonald AM; Jacob R; Dobelbower MC; Kim RY; Fiveash JB
    Acta Oncol; 2013 Aug; 52(6):1181-8. PubMed ID: 23544356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
    Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
    Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.
    Hashimoto Y; Motegi A; Akimoto T; Mitsuhashi N; Iizuka J; Tanabe K; Ishii Y; Kono S; Izumi S; Karasawa K
    Int J Clin Oncol; 2018 Feb; 23(1):165-172. PubMed ID: 28758177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current status of intensity-modulated radiation therapy for prostate cancer: History, clinical results and future directions.
    Hatano K; Tohyama N; Kodama T; Okabe N; Sakai M; Konoeda K
    Int J Urol; 2019 Aug; 26(8):775-784. PubMed ID: 31115116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity.
    Valeriani M; Carnevale A; Osti MF; Minniti G; De Sanctis V; Agolli L; Bracci S; Enrici RM
    Tumori; 2013; 99(4):474-9. PubMed ID: 24326835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.
    Wong WW; Schild SE; Vora SA; Ezzell GA; Nguyen BD; Ram PC; Roarke MC
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e423-9. PubMed ID: 21477947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.
    Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
    Dearnaley D; Syndikus I; Sumo G; Bidmead M; Bloomfield D; Clark C; Gao A; Hassan S; Horwich A; Huddart R; Khoo V; Kirkbride P; Mayles H; Mayles P; Naismith O; Parker C; Patterson H; Russell M; Scrase C; South C; Staffurth J; Hall E
    Lancet Oncol; 2012 Jan; 13(1):43-54. PubMed ID: 22169269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.